vessel wall and infiltration by smooth muscle cell (SMC). Thus, a bioabsorbable stent might have less potential for late stent thrombosis than a drug eluting stent because there will be no foreign material exposed to blood if endothelization delayed or incomplete than a drug eluting metallic stent. 11 Since, its introduction, the uses of BVS with its potential effects in reducing restenosis with maintaining the integrity of vessel has been well established. To see the clinical outcome of the BVS ABSORB vascular scaffold in treating denovo coronary artery stenosis, we have carried out this prospective cohort study and followed up by noninvasive clinical assessment in our cardiac outpatients department.
Methods:
Study design: Uses of BVS was approved by the local ethics committee, and all patients gave written consent after briefing in detail about the BVS stent. In brief, patients were eligible for the study if they had single de novo native coronary lesions that could be covered with a single BVS and were included in the study. Patient were ineligible if the had evolving myocardial infarction, left main coronary artery lesion, an ostial lesion, a bifurcation lesion, a totally occluded lesion, a lesion with moderate to heavy calcification and were excluded from the study. Patients were followed up clinically at 6-8 weeks interval. Drug Therapy: All the patients received Aspirin 300 mg/day and Clopidegrol as a loading dose 300 mg prior to PCI, kept on for initial 9-12 months and advised to continue up till next 24 month. Patient also received atorovastatin along with standard Medical management for CAD. During the procedure, an intravenous heparin bolus (100IU/Kg) administered and the use GP IIb/IIIa receptor blocker was as per individual operator discretion. Quantitative angiographic measurements of the target lesion were obtained in order to deploy correct size stent.
Safety measure: All patients were followed up at a regular interval of 6-8wks in our cardiac outpatient department. To ensure the safety and efficacy of the devices, all patients were considered to assess clinically for the development of chest pain, hypotension, heart failure or Myocardial Infarction. In the event, if any, postprocedural CK-MB, ECG and Echo were advised.
Statistical analysis: Data were presented as mean ± SD with percentage.. Table I . Shows the profile of studied population. Female patients were more obese (BMI; M 25: F 27) and developed CAD in advance age (M 56: F 60). CAD risk factors were more in male than female. Territory wise distribution of BVS Absorb stent, were for: LAD 6(30%), RCA 9 (45%), and LCX 5 (25%). Fig 3. Common stented territory were for: LAD 6 (37.5%), LCX 5 (25%), RCA 6(37.5%). Data were presented as Mean ± SD
Results:

Discussion:
In this non-randomized prospective cohort, all the patients were treated with BVS Absorb vascular scaffold eluting with Everolimus and followed up clinically on regular interval in the cardiac outpatient department. In this very preliminary study, only simple lesion were selected and treated with a BVS stent after predilatation of the culprit lesion. Complex lesion, CTO lesion and calcific lesion were excluded from the protocol. Patients were followed up by noninvasive means in the cardiac outpatient department of this hospital.
PTCA has been established as an alternative to coronary artery bypass surgery to treat selected patients with coronary artery disease. However, success of PTCA is limited by acute vessel occlusion and late restenosis. Stents were developed to overcome these issues, and first clinical application with metallic stent was conducted in 1986. 3 All currently available stents, they induce varying degree of thrombogenesis and significant intimal hyperplasia. Late thrombosis may be another potential risk.
Stent malposition in cases of plaque shrinkage or positive vessel remodeling can also occur. Furthermore, metallic stent could preclude surgical revascularization and jail-sided branches, prevent expansive remodeling, eliminate reactive vasomotion and impairing the non-invasive imaging of coronaries by CT and MRI. Restenosis commonly occur within 3 to 6 months after coronary intervention. 10 Therefore; the clinical need for stent scaffolding is limited after this period. Considering the short term need and the potential for long-term complications with metallic stents, stents made of biodegradable materials may be an ideal alternative. Tamai et al, 15 demonstrated that the PLLA stents do not showed any stent thrombosis or early stent recoil. And at 6 month follow up all patients showed acceptable restenosis and target lesion revascularization, and no MI or CABG were recorded. Thus PLLA stents can be an attractive alternative to metallic stents and serve as a useful vehicle for locally administered drugs. Although, the first generation of BVS showed a slightly higher acute recoil and at 6 months an 11.8% reduction of in scaffold area and a 24.3% decrease in minimal luminal area were documented and dubbed late recoil. 12, 13 To minimize these recoil, the BVS revision 1.1 was tested in 101 patients of the ABSORB cohort B study and demonstrated that modified manufacturing process of the polymer and geometric changes in the polymorphic platform have substantially improved the performance to become comparable with current DES. 14 Because of the biodegradable feature, longer-term follow up with multiple comparative study necessary to prove its superiority over the available metallic DES. In this regard, more patients need to include in the registry and to do randomize study to determine its safety and efficacy of PLLA stent coated with Everolimus in our population.
Several on going trials of BVS Absorb are promising, Tamai, et al, 15, 16 showed long term results similar to those of after BMS implantation, leading support to the feasibility and safety of a bioabsorbable PLLA polymer stent. The absorb trial 17 showed, the overall 16.8% reduction of the luminal area at 6 months due to a mild shrinkage of the stent area. The only major adverse cardiac event was a non-Q MI in one patient. After 2 years the biodegradable stent was incorporated into the vessel wall with the documented restoration of vasomotion suggest healing of the artery. In addition, it appeared that the vessel lumen enlarged and the plaque/media diminished. 18 The 3 year clinical outcome is quite encouraging: ID-MACE is 3.4% without any late complication. Since, the first generation BVS Everolimus stents showed signs of shrinkage at 6 months, modified manufacturing process of the polymer and geometric changes in the polymeric platform substantially improved the medium term performance of this new generation drug eluting scaffold to be comparable to those with currently available DES. 14 Thus, the absence of a foreign body and restoration of vasomotion raise the hope of abnormal healed vessel that could be without the risk of thrombosis.
In our present perspective of non-randomized cohort, total 20 stents were deployed in 17 territories of total 16 patients. 3 patients has overlapped stented segment. One patient has double vessel stent. Large size BVS scaffold was used in RCA. Because of the small number of patient, it was very difficult to address whether BVS ABSORB vascular scaffold eluted with the drug everolimus is superior over the other available metallic DES. No stent fracture during the deployment and acute or sub-acute stent restenosis occurred in the study. Careful consecutive predilatation of the culprit lesion before the stent deployment was mandated and postdilatation was done to ensure better stent apposition.
We need more patient inclusion, randomization into PCI with BVS absorb and with DES metallic stents to compare the superiority of PCI of BVS ABSORB. In addition, we need to address the superiority of BVS absorb Everolimus drug eluting stents over DES metal stents in treating coronary stenosis. In this regard, we need multicenter study in perspective of Bangladeshi patient population. We need to address the impact of CAD risk factor, overlapped stent, dual anti-platelet therapy (DAPT) has any role in inducing stent thrombosis and the development of instent restenosis in the patient treated with BVS vascular scaffold.
Study Limitations: We don't have intravascular ultrasonogram (IVUS) and Fractional Flow Reserve (FFR)
Conclusion:
BVS ABSORB Everolimus eluting vascular scaffold for treating de novo coronary artery stenosis in our patient perspective showed excellent clinical safety with no major adverse cardiac event at 9 month clinical follow up at our center. To address its superiority compare to other available drug eluting stent, we need more randomized comparative study.
